Comparison of the effect of intravenous morphine with intravenous ketorolac in relieving pain in patients with limb fractures referred to the emergency department

Comparison of the effect of intravenous morphine with intravenous ketorolac in relieving pain in patients with limb fractures referred to the emergency department of Khatam An-bia Hospital in Zahedan in 2022

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054869N3

Enrollment

Registered

2022-11-18

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain management in patients with limb fractures. Acute pain due to trauma

Interventions

Intervention 1: Intervention group: Intravenous ketorolac 30 mg, 1 cc of Caspian Daru Company, which is administered intravenously to the patient within 5 minutes after the patient enters the study a

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Existence of definitive limb fracture based on radiography and pain intensity based on visual analog scale more than 4

Exclusion criteria

Exclusion criteria: Lack of informed consent Hemodynamic instability Underlying pulmonary problems, History of taking painkillers or narcotic drugs History of liver or kidney disease Head injury Pregnancy Age below 15 years and above 60 years

Design outcomes

Primary

Measure	Time frame
Pain score. Timepoint: Before the intervention and 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Visual Analogue Scale (VAS).	—

Secondary

Measure	Time frame
Respiratory depression. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Headache. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Dizziness. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Drowziness. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.	—

Measure

Time frame

Respiratory depression. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Headache. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Dizziness. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.;Drowziness. Timepoint: 10, 20, 40, 60, 75 minutes after the intervention. Method of measurement: Having or not having a side effect after the intervention.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Abdolrazaghnejad

Zahedan University of Medical Sciences

ali.abdorazzagh@gmail.com+98 54 3323 2890

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026